openPR Logo
Press release

Synovial Sarcoma Therapeutics - Key Players Analysis Takara Bio Inc., Oncolytics Biotech Inc., Cue Biopharma

12-13-2018 06:49 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: P&S Intelligence

Synovial Sarcoma Therapeutics - Key Players Analysis Takara Bio

The study analysed that the Synovial sarcoma pipeline comprises of 22 drug candidates in different stages of development.

Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females. Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis/report-sample

New innovating technologies offer development of promising drugs

Many technologies such as REOLYSIN technology, ZVex and GLAAS technology, Laser Micro-beam Microdissection are being developed that can bring the innovative treatment, which can control the progression of Synovial sarcoma. ZVex and GLAAS are complementary discovery platforms designed to activate and expand the immune system’s natural ability to create tumour-specific cytotoxic T cells (CTLs) in vivo.

Browse report at: https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis

*Major companies collaborate for the development of Synovial Sarcoma Pipeline

The research also found that various companies have collaborated for the development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc. (Merck) agreed to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two of the Pfizer’s oncology assets.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=synovial-sarcoma-therapeutics-pipeline-analysis

Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Synovial Sarcoma Therapeutics - Key Players Analysis Takara Bio Inc., Oncolytics Biotech Inc., Cue Biopharma here

News-ID: 1436962 • Views:

More Releases from P&S Intelligence

U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
According to the latest market research study published by P&S Intelligence, the U.S. Environmental, Social, and Governance (ESG) investments market is experiencing a significant surge, with projections indicating an increase from $6.5 trillion in 2024 to an estimated $16.0 trillion by 2032. This represents a robust compound annual growth rate (CAGR) of 12.1% over the forecast period. According to a comprehensive analysis by P&S Intelligence, the market's expansion is driven
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sectors
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sec …
According to the latest market research study published by P&S Intelligence, the U.K. facility management market is poised for significant growth, with projected revenues reaching USD 2,743.3 million in 2024 and expected to soar to USD 6,038.4 million by 2030, reflecting a robust CAGR of 14.1% during the forecast period. This expansion is fueled by a surge in demand across both public and private sectors. According to the RICS U.K.
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by Omnichannel Integration
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by O …
According to the latest market research study published by P&S Intelligence, the U.S. point-of-sale (POS) software market, valued at USD 4.7 billion in 2024, is poised for significant growth over the coming years, with projections estimating it will reach USD 9.8 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.7%. This growth is attributed to rapid technological advancements, a surge in mobile and cloud-based POS systems,
Competitive Landscape of the Industrial Starches Market: Key Players, Trends, and Growth Opportunities
Competitive Landscape of the Industrial Starches Market: Key Players, Trends, an …
According to the latest market research study published by P&S Intelligence, the global industrial starches market is poised for significant growth, with a projected increase from USD 110.3 billion in 2024 to USD 169.9 billion by 2030, at a robust compound annual growth rate (CAGR) of 7.5%. Industrial starches play a crucial role in diverse sectors, including food, pharmaceuticals, and paper, driven by their unique properties such as stabilizing, thickening,

All 4 Releases


More Releases for Synovial

Synovial Sarcoma Market Clinical Advancements and Commercial Forecast
Synovial sarcoma is a rare, aggressive soft tissue cancer that typically arises near the joints of the arm or leg but can occur in other parts of the body. Although it accounts for less than 10% of all soft tissue sarcomas, synovial sarcoma often affects young adults and adolescents, making it a critical area of oncology research. Due to limited treatment options and poor survival outcomes, there has been an
Synovial Sarcoma Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Synovial Sarcoma Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the Synovial Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Synovial Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Synovial
Synovial Sarcoma Market Size, Share, Report and Forecast 2024-2032
The synovial sarcoma market size is anticipated to grow at a CAGR of 4% during the forecast period of 2024-2032, driven by increasing research activities in targeted therapy development. Synovial Sarcoma: Introduction Synovial sarcoma is a rare and aggressive type of soft tissue cancer, primarily affecting young adults. It often arises near large joints, especially the knees, though it can occur anywhere in the body. Despite its name, it's not related to
Synovial Sarcoma Market Size, Trends, Industry Value and Latest Insights Till 20 …
What is the market size of synovial sarcoma? The synovial sarcoma market reached a value of US$ 75.3 Million in 2023 and expected  to reach US$ 114.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034. Request for a Sample of this Report: https://www.imarcgroup.com/synovial-sarcoma-market/requestsample Synovial Sarcoma Market Trends: Synovial sarcoma is a rare and aggressive form of soft tissue cancer that primarily affects young adults. Despite its rarity, the market for
Synovial Sarcoma Market Analysis: Growth, Trends, and Key Players
The Synovial Sarcoma Market is set for substantial expansion, with an anticipated Compound Annual Growth Rate (CAGR) of 4% during the forecast period spanning from 2024 to 2032. This growth can be attributed to various factors such as the increasing incidence of synovial sarcoma, advancements in medical technology, and the development of targeted therapies. In this comprehensive blog post, we will provide an in-depth overview of the Synovial Sarcoma Market,
Synovial Sarcoma Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Synovial Sarcoma, historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Synovial Sarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Synovial Sarcoma market size